Business
Halberd Corporation Alzheimer's Disease Treatment Tests Yield Outstanding Results
Halberd Corporation Alzheimer's Disease Treatment Tests Yield Outstanding Results.
About this update from Halberd Corp.
[{"type":"text","content":"JACKSON CENTER, PA / ACCESSWIRE / August 30, 2021 / Halberd Corp. (OTC PINK:HALB) provided an update on its Alzheimer's Disease eradication experimentation being conducted at Youngstown State University (YSU) and Arizona State University (ASU). Following standard scientific methodology, Halberd conducted two rounds of experimentation on Phosphorylated Tau, and the results were so astounding that the researchers want to conduct further replication tests prior to publication in scientific articles.Bodily fluids treated with nanoparticles conjoined to specific antibodies attract and adhere to target disease antigens. These conjoined target antigens are subjected to laser emissive energy and to radio frequency waves in separate experiments. Halberd's initial target disease antigen, Phosphorylated Tau, is the primary building block of neurofibrillary tangles associated with the onset and progression of Alzheimer's Disease and other neurodegenerative diseases.William A. Hartman, Halberd Corporation's Chairman, President & CEO, stated. "Once the replication testing is completed, our researchers will commence writing scientific articles on the technology and results. These tests and the scientific documents should be completed within the next several weeks. Testing on the other antigens associated with Alzheimer's Disease will commence at that time.""Halberd's previous testing on E. Coli also yielded stunningly positive results, which are also being replicated prior to publication," Hartman concluded.To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.(https://halberdcorporation.com/contact-us/)For more information please contact:William A. [email protected]@halberdcorporation.comwww.halberdcorporation.comTwitter:@HalberdCAbout Halberd Corporation.Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It holds the exclusive worldwide rights to several patent- and PCT-pending extracorporeal treatments for COVID-19 and other medical maladies.Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287 and an allowed but not yet issued patent ...